3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Hodgkin Disease
11
Neoplasms
2
Mycosis Fungoides
2
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphomatoid Papulosis
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
32
Cisplatin
22
pembrolizumab
21
Magnetic Resonance Spectroscopy
18
Specimen Handling
16
durvalumab
12
Mitomycin
10
enfortumab vedotin
9
avelumab
9
Nivolumab
9
Cystoscopy
9
Fluorouracil
8
Carboplatin
8
Radiation
7
Cystectomy
7
Immunoglobulin G
6
Docetaxel
6
Disulfides
6
atezolizumab
5
Transurethral Resection of Bladder
5
Radiotherapy
5
Mitozytrex
5
Biopsy
5
tremelimumab
4
sacituzumab govitecan
4
erdafitinib
4
dehydroftorafur
4
Platinum
4
1,2-diaminocyclohexaneplatinum II citrate
4
disitamab vedotin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Brentuximab Vedotin
×
90 days
×
Clear all
No trials found.